ASTRAZEN2024-10-012024-12-31 ASTRAZEN2024-10-012024-12-31 ASTRAZEN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ASTRAZEN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member ASTRAZEN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member ASTRAZEN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ASTRAZEN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member ASTRAZEN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member ASTRAZEN2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 506820 ASTRAZEN NA AstraZeneca Pharma India Limited Equity 2024-04-01 2025-03-31 2025-02-11 2025-01-20 INR Millions Third quarter 14:30:00 17:30:00 2025-02-11 2025-02-11 Not applicable Single segment Healthcare 2024-10-01 2024-12-31 Unaudited Standalone 4402890000.00 79820000.00 4482710000.00 698840000.00 2287610000.00 -516050000.00 623650000.00 3280000.00 90740000.00 538960000.00 3727030000.00 755680000.00 -335490000.00 420190000.00 121680000.00 -10000000.00 111680000.00 0.00 308510000.00 0.00 0.00 0.00 0.00 308510000.00 -17170000.00 291340000.00 0.00 0.00 50000000.00 2 12.34 12.34 0.00 0.00 12.34 12.34 Notes: 1 The Statements of unaudited financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. 3 Exceptional items a Exceptional items for the quarter and nine months ended 31 December 2024 consists of employee separation cost amounting to Rs. 335.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome. b In continuation with the Company’s earlier announcement of intent to exit its manufacturing site on 16 November 2023, the Company explored the option of sale of the manufacturing site in a fully operational manner to a Contract Manufacturing Organisation. The Company was unable to find a suitable one and has made an announcement to Stock exchanges on 21 June 2024 that it will now explore a buyer for its manufacturing site and exit in due course. The exit is estimated to take more than 12 months. Consequently, the Company has accounted for provisions related to closure of its manufacturing site amounting to Rs.575.6 Million as exceptional item for the nine months ended 31 December 2024 as per the relevant Indian Accounting Standards. c The Company had entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs.164.3 Million is disclosed as an exceptional income for the nine months ended 31 December 2023 and year ended 31 March 2024. 4 This Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 11 February 2025. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter and nine months ended 31 December 2024. 5 The Company has decided to change the rounding off principle followed in the Statement of financial results from lakhs of rupees to millions of rupees from the quarter ended 30 June 2024. By Order of the Board of Directors For AstraZeneca Pharma India Limited Place: Bengaluru Sanjeev Kumar Panchal Date: 11 February 2025 Managing Director Single segment 2024-04-01 2024-12-31 Unaudited Standalone 12358060000.00 244840000.00 12602900000.00 1928810000.00 7209640000.00 -2104370000.00 1913660000.00 7810000.00 223010000.00 1734340000.00 10912900000.00 1690000000.00 -911090000.00 778910000.00 376190000.00 -172170000.00 204020000.00 0.00 574890000.00 0.00 0.00 0.00 0.00 574890000.00 -26340000.00 548550000.00 0.00 0.00 50000000.00 2 22.99 22.99 0.00 0.00 22.99 22.99 Allowance for expected credit loss (net) -1690000.00 Other Expenses 313250000.00 Selling, marketing and distribution expenses 227400000.00 Allowance for expected credit loss (net) 15980000.00 Other Expenses 1089860000.00 Selling, marketing and distribution expenses 628500000.00 -22950000.00 -35190000.00 -5780000.00 -8850000.00 0.00 0.00